Clinical Trials

Building on clinical trial and laboratory research insights from the past decade, the ITN has focused and deliberate strategies to achieving tolerance in each disease area. The research supported by the ITN has unlocked new therapeutic approaches and discovered new biomarkers that promise to change the way physicians treat patients. Explore ITN clinical trials below by using a search term or by sorting the specific trial categories. If you have questions or want more information about ITN clinical trials, contact us.

Principal Investigator:

Patrick Holt | University of Western Australia | CRAWLEY, WA

Peter Sly | | Subiaico, WA

The purpose of this study is to determine whether early childhood exposure to common allergens (substances that can trigger allergies and asthma) can prevent the development of asthma in children at high risk for developing the disease.

Category: 

Allergy & Asthma

|

Specific Category: 

Allergy/Asthma

|

Status: 

Complete

Principal Investigator:

J. Richard Thistlethwaite | University of Chicago | Chicago, IL

This study will determine whether treatment with alemtuzumab and tacrolimus is effective in preventing organ rejection and maintaining the recipient's health after liver transplantation in patients with end-stage liver disease, and whether gradual tapering of tacrolimus treatment is safe for these patients.

Category: 

Transplantation

|

Specific Category: 

Liver Transplantation

|

Status: 

Complete

Principal Investigator:

Flavio Vincenti | University of California San Francisco | San Francisco, CA

Chris Larsen | Emory University | Atlanta, GA

Belatacept is an experimental medication shown in clinical trials to have immune system suppression properties in people who have had kidney transplants. This study will determine whether a combination of anti-rejection drugs, including belatacept, can prevent the rejection of a first-time, non-HLA identical kidney transplant and allow patients to be safely withdrawn from anti-rejection therapy one year post-transplant.

Category: 

Transplantation

|

Specific Category: 

Kidney Transplantation

|

Status: 

Complete

Principal Investigator:

George W. Burke | University of Miami Miller School of Medicine | Miami, FL

Alemtuzumab is a man-made antibody used to treat certain blood disorders. This study will evaluate treatment of kidney transplant recipients with alemtuzumab and other immune system suppressing medications with or without infusions of bone marrow stem cells from the kidney donor. The purpose of this study is to find out which strategy is more effective in preventing organ rejection and maintaining patient health.

Category: 

Transplantation

|

Specific Category: 

Kidney Transplantation

|

Status: 

Complete

Principal Investigator:

John Stone | Johns Hopkins University | Baltimore, MD

Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating adults with WG and MPA.

Category: 

Autoimmune Disease

|

Specific Category: 

ANCA Positive Vasculitis

|

Status: 

Complete

Principal Investigator:

Scott Zamvil | University of California San Francisco | San Francisco, CA

Patients who have been diagnosed with clinically isolated syndrome (CIS) often develop problems related to the central nervous system, which controls the nerves in the body. Some of these patients may later be diagnosed with multiple sclerosis (MS), a progressive disease of the nervous system. The purpose of this study is to determine if the drug atorvastatin is helpful to CIS patients.

Category: 

Autoimmune Disease

|

Specific Category: 

Clinically Isolated Syndrome

|

Status: 

Complete

Principal Investigator:

Thomas Casale | Creighton University | Omaha, NE

A series of allergy shots may reduce symptoms of seasonal ragweed allergies. This study will determine whether taking a drug called omalizumab (also known as Xolair) before getting the allergy shots is more effective than allergy shots alone or other treatments, such as prescription antihistamines.

Category: 

Allergy & Asthma

|

Specific Category: 

Ragweed Allergy

|

Status: 

Complete

Principal Investigator:

Carla Greenbaum | Benaroya Research Institute | Seattle, WA

This is a phase I trial in individuals who have been diagnosed with type 1 diabetes within the previous 3-48 months. The study is testing whether two immune system modifying drugs are safe when used in combination and if they have immune altering effects that indicate they can halt the progression of type 1 diabetes.

Category: 

Type 1 Diabetes

|

Specific Category: 

Type 1 Diabetes

|

Status: 

Complete

Principal Investigator:

Stuart Knechtle | Emory University | Atlanta, GA

The purpose of this study is to test the safety and effectiveness of using alemtuzumab in combination with two other drugs, sirolimus and tacrolimus, to prevent organ rejection after kidney transplantation. This study will also test whether this combination of medications will allow patients to eventually stop taking antirejection medications entirely.

Category: 

Transplantation

|

Specific Category: 

Kidney Transplantation

|

Status: 

Complete

Principal Investigator:

Tihamer Orban | Joslin Diabetes Center, Harvard Medical Center | Cambridge, MA

In addition to regulating blood sugar, insulin may have the ability to protect cells in the pancreas from attack by the immune system. This study will evaluate whether an insulin-based vaccine can protect cells from autoimmune destruction.

Category: 

Type 1 Diabetes

|

Specific Category: 

Type 1 Diabetes

|

Status: 

Complete

No items found.